P390 IMPACT IN DAILY PRACTICE OF THE CONCEPT OF TREATMENT RESPONSE IN PRIMARY BILIARY CIRRHOSIS. A NATIONAL COHORT STUDY
โ Scribed by Leeman, M.; Lammers, W.J.; Ponsioen, C.Y.; Boonstra, K.; van Erpecum, K.J.; Wolfhagen, F.H.J.; Kuyvenhoven, J.P.; Vrolijk, J.M.; Drenth, J.P.H.; Witteman, E.M.; van Nieuwkerk, C.M.J.; van der Spek, B.W.; Witteman, B.J.M.; Erkelens, G.W.; Verhagen, M.A.M.T.; van Tuyl, S.A.C.; Poen, A.C.; Brouwer, J.T.; ter Borg, F.; Koek, G.H.; van Ditzhuijsen, T.J.M.; Hansen, B.E.; van Buuren, H.R.
- Book ID
- 122289596
- Publisher
- Elsevier Science
- Year
- 2014
- Tongue
- English
- Weight
- 89 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC). However, some patients show an incomplete response to UDCA therapy. Treatment with corticosteroids may be of benefit although at the expense of systemic side effects. Budesonid